Symbiotec Pharmalab Limited
NSE: SYMBIOTECPharmaceuticals
Share price
₹1,093.80
-3.68% close of 8 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 6 Oct 2026, the close above is 8 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
60
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹7,110 Cr
P/E ratio
61.8
P/B ratio
—
ROCE
13.0%
ROE
11.7%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 6.2% a year against a sector median of 13.1% — 6.9 percentage points slower.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 0.9 times its growth rate, on earnings growth of 70%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Symbiotec Pharmalab Limited — this one | 70%/yr | 61.8× | ₹0.88 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 74 of 130 on returns, 95 of 127 on growth, 35 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 13% on capital, ahead of 43% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the last five years it made ₹497 crore of cash from the business but spent ₹1040 crore on plant and equipment, ₹543 crore more than it made; the gap was from lenders and shareholders. And the profit is real: of every 100 rupees it reported over 6 years, about 126 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 121 days for its cash to paid 22 days before it paid its own suppliers.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 8 checks clear · 75%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 21 Sep 2026 · Consolidated · Unaudited
Revenue
₹218 Cr
Revenue vs last year
+7.4%
Net profit
₹14 Cr
Profit vs last year
-53.1%
Net margin
6.4%
EPS
₹2.24
Earnings call transcript · 22 Sep 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹7,110 Cr
- Prev close
- ₹1,093.80
- 52w High
- ₹1,246
- 52w Low
- ₹934
- Enterprise value
- ₹7,407 Cr
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 6.2%
- PEG ratio
- 1.0
- P/E ratio
- 61.8
- P/B ratio
- —
- EV / EBITDA
- 31.0
- Industry P/E
- 38.0
- ROCE
- 13.0%
- ROCE 5y average
- 13.4%
- ROE
- 11.7%
- Debt / Equity
- 0.3
- Interest coverage
- 6.9
- Dividend yield
- 0.0%
- ROE 3y average
- 13.0%
- ROE last year
- 12.0%
Annual P&L
- Annual revenue
- ₹869 Cr
- Annual profit
- ₹110 Cr
- Operating margin
- 27.0%
- Net profit margin
- 12.7%
- EBITDA margin
- 27.5%
- Sales growth 3y
- 15.3%
- Sales growth 5y
- 6.5%
- Profit growth 3y
- 70.0%
- Profit growth 5y
- -1.0%
- EPS
- ₹17.5
- Sales growth TTM
- 16.0%
- Profit growth TTM
- 19.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹218 Cr
- Profit latest quarter
- ₹14 Cr
- YoY quarterly sales growth
- 7.3%
- YoY quarterly profit growth
- -53.3%
- OPM latest quarter
- 21.0%
Balance Sheet
- Book Value
- ₹177
- Face Value
- ₹2.0
- Total debt
- ₹391 Cr
- Total cash
- ₹10 Cr
- Borrowings
- ₹391 Cr
- Reserves / Equity
- 87.5
Cash Flow
- Operating cash flow
- ₹175 Cr
- Free cash flow
- -₹50 Cr
- FCF yield
- -1.1%
- Net cash flow
- -₹16 Cr
Shareholding
- Promoter holding
- 33.3%
- FII holding
- 21.1%
- DII holding
- 27.5%
- Public holding
- 18.1%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,779.70 | 33.8 | 4,27,010 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,196.00 | 81.9 | 2,44,125 | 0.33 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,772.00 | 81.3 | 1,81,512 | 0.80 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,139.00 | 23.3 | 1,13,616 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Cipla | 1,335.50 | 30.1 | 1,07,891 | 0.97 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Laurus Labs | 1,971.40 | 97.4 | 1,06,517 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Mankind Pharma | 2,479.00 | 48.0 | 1,02,394 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Symbiotec Pharma | 1,169.70 | 75.6 | 7,516 | 0.00 | 14.1 | -53.0 | 218.2 | 7.4 | 13.0 |
| Median | 411.30 | 34.2 | 2,145 | 0.06 | 13.2 | 29.6 | 160.3 | 18.6 | 14.9 |
Competes with: ABH Healthcare Limited, Cipla, Cohance Lifesciences Limited, Concord Biotech Limited, Divi's Laboratories, Dr Reddy's Laboratories, Hy-Tech Engineers Limited, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Skyways Air Services Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 203 | 245 | 218 |
| Expenses | 145 | 183 | 173 |
| Material Cost | 103 | ||
| Change in Inventories | -27 | ||
| Purchases of Stock-in-Trade | 0 | ||
| Employee Cost | 46 | ||
| Other Expenses | 51 | ||
| Operating Profit | 58 | 62 | 45 |
| OPM % | 29 | 25 | 21 |
| Other Income | 3 | 0 | 0 |
| Exceptional items (within Other Income) | 0 | ||
| Interest | 5 | 7 | 6 |
| Depreciation | 11 | 20 | 22 |
| Profit before tax | 45 | 35 | 18 |
| Tax % | 33 | 22 | 20 |
| Net Profit | 30 | 28 | 14 |
| EPS in Rs | 47 | 4.39 | 2.24 |
| Diluted EPS in Rs | 2.24 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31 | 19 | 12 | 24 | 27 | 27 |
| Other Income | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28 | 27 | 38 | 23 | 34 | 28 |
| Net Profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 113 | 71 | 21 | 91 | 152 | 18 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 7%
- 3 years
- 15%
- TTM
- 16%
Compounded profit growth
- 10 years
- —
- 5 years
- -1%
- 3 years
- 70%
- TTM
- 19%
Return on equity
- 10 years
- —
- 5 years
- 12%
- 3 years
- 13%
- Last year
- 12%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | 18 | 6 | 16 | 14 | 13 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
News
News and filings about Symbiotec Pharmalab Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Exports to
- United States
Sells to
- Cipla · high-quality Active Pharmaceutical Ingredients (APIs)
- GlaxoSmithKline (GSK) · high-quality Active Pharmaceutical Ingredients (APIs)
- Teva Pharmaceutical · high-quality Active Pharmaceutical Ingredients (APIs)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE899I01028
Plants
- Mhow Facility · Mhow, Madhya Pradesh
- Pithampur Facility (SEZ) · Pithampur, Madhya Pradesh
- Rau Facility · Indore, Madhya Pradesh
- Ujjain Facility · Ujjain, Madhya Pradesh
News impact
Big market events that reach Symbiotec Pharmalab Limited, and how the effect spreads.
29 Sept, 18:35 IST · Market event · medium impact
Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report
Sun Pharma plans a Rs 10,000 crore bond sale to refinance its Organon deal, slightly hurting Sun Pharma shareholders on higher leverage while leaving drug rivals largely unaffected.
Who it hits first
- Sun Pharmaceutical, India's biggest drugmaker by market value, plans to raise Rs 10,000 crore by selling rupee bonds maturing in two, three and four years.
- The money will refinance borrowings tied to its Organon deal, swapping old deal loans for new bonds rather than funding new factories or drugs.
- Existing Sun Pharma shareholders face mild pressure from higher interest costs and extra bond supply, partly offset by longer, possibly cheaper maturities.
Who may gain
- Bond buyers and mutual funds gain fresh, highly rated Sun Pharma paper across 2-4 year maturities.
- The banks and arrangers running the Rs 10,000 crore sale earn underwriting fees.
- Long-term Sun Pharma holders could benefit if the new bonds carry lower rates than the old deal debt.
Along the supply chain
Downstream
No downstream effect — Sun Pharma sells finished medicines, and a bond refinancing does not change drug prices, chemist stocks or patient demand.
Upstream
No direct supply-chain link — Divi's Laboratories and other ingredient suppliers to Sun Pharma keep the same orders, since refinancing changes lenders, not production.
Where demand moves
Business
No new drug demand is created — hospitals, chemists and patients buy the same medicines; the only business flow is Sun Pharma swapping one lender for another.
Capital
About Rs 10,000 crore of investor money flows into new Sun Pharma bonds while the repaid Organon deal loans release bank capital for other borrowers, and Sun Pharma shares may see mild selling as leverage headlines weigh.
How it spreads across sectors
Healthcare
Neutral for drug peers — a single company's refinancing moves no industry sales or prices, so rivals from Cipla to Lupin should trade flat.
IT Services
No spillover — the 'Rupee Cascade' keyword fired only because the bonds are rupee-denominated, not because the currency moved, so export-earning sectors see no chain.
A pattern seen before
Cascade chain
Pattern name
Rupee Cascade
Patterns
- Rupee Cascade
Sectors queried
- IT Services
- Oil & Gas
- Pharma
When it plays out
Immediate
Sun Pharma shares drift mildly on the leverage headline while bond arrangers sound out investors for the 2-4 year tranches.
Medium term
Higher interest costs show up in quarterly results; if rates fell, refinancing savings support earnings instead.
Short term
Bond pricing and demand decide the verdict — a well-bought issue calms equity, a weak one extends the drag.
26 Sept, 23:54 IST · Market event · high impact
Zydus Lifesciences’ New Jersey facility clears USFDA inspection with nil observations
Zydus Lifesciences cleared a US drug-safety inspection in New Jersey with no observations, lifting Zydus shares while rival drug makers see little direct effect.
Who it hits first
- Zydus Lifesciences, the Ahmedabad-based drug maker, had its New Jersey site's drug-safety monitoring system inspected by the US Food and Drug Administration from September 22 to 25.
- The inspection closed with nil (zero) observations, meaning the inspectors found no problems needing corrective action.
- This removes a near-term regulatory worry for Zydus's US business but does not by itself create new sales.
Who may gain
- Zydus Lifesciences — lower US regulatory risk and steadier sentiment for its existing US drug sales.
- Zydus shareholders — reduced overhang of a warning letter or import restriction at this New Jersey site.
Along the supply chain
Downstream
US distributors, pharmacies and patients see continued supply confidence, but no price or volume shift — this clearance does not approve a new drug.
Upstream
Ingredient, packaging and service suppliers to Zydus see no direct order change — a clean safety-system inspection keeps existing production running rather than adding new volume.
Where demand moves
Business
No new purchase orders flow from this clearance — it is a compliance pass, not a contract win — but it protects Zydus's existing US drug sales from disruption.
Capital
Investors are likely to give Zydus a small relief premium as US regulatory risk falls, with little fresh money moving into rival drug stocks on this news alone.
How it spreads across sectors
Healthcare
Mild positive sentiment for Indian drug exporters on clean USFDA news, but no sector-wide earnings change since the clearance is specific to one Zydus site.
When it plays out
Immediate
1-7 days: Zydus shares firm modestly on relief; rival drug stocks barely move.
Medium term
1-6 months: no lasting uplift unless followed by new US approvals or launches linked to the site.
Short term
1-4 weeks: focus shifts back to Zydus's US pipeline and pricing; the inspection fades as a price driver.
15 Sept, 20:53 IST · Market event · medium impact
Dr. Reddy's Laboratories launches Nivorz in India
Dr Reddy's launched Nivorz, its first biosimilar cancer-immunotherapy drug in India, opening a new premium revenue stream for itself; biosimilar rival Biocon bears watching but no proven share loss yet, and suppliers and other drug makers are barely touched.
Who it hits first
- Dr Reddy's Laboratories has launched Nivorz in India — its first biosimilar cancer immunotherapy drug, marking the company's entry into biosimilar immuno-oncology.
- The direct gain lands on Dr Reddy's alone: a new high-value cancer-drug revenue stream that starts small (new prescriptions and hospital approvals take time) and builds over coming quarters.
Who may gain
- Dr Reddy's itself is the main beneficiary: Nivorz adds a premium oncology label beyond its usual low-cost generics and supports a richer valuation if uptake is strong.
- Cancer hospitals and patients benefit at the margin: a locally made biosimilar should cost less than imported original drugs, widening access — though no launch price was disclosed.
Along the supply chain
Downstream
Hospitals, oncology distributors and pharmacies simply gain one more lower-priced cancer-immunotherapy option to stock; no shortages, no disruption, no pricing shock anywhere in the chain.
Upstream
Almost no upstream effect: biosimilars are grown in living cells in specialised plants, mostly in-house, so Dr Reddy's chemical-ingredient suppliers (Divi's, Laurus) see no direct order uplift — any gain for them is sentiment only.
Where demand moves
Business
No new demand is created — cancer-drug demand already exists. A small share of spending shifts toward Dr Reddy's lower-priced Nivorz from the imported original and any existing sellers, while lower prices may expand the treated-patient pool slightly.
Capital
No sector rotation: at most a mild positive re-rating of Dr Reddy's on the biosimilar-entry story; pharma money has no reason to move between rivals on a single domestic launch with no sales numbers yet.
How it spreads across sectors
Healthcare
Mild validation of the domestic biosimilar theme: another big Indian maker moving up into complex cancer biologics comforts the sector's growth story, while biosimilar leader Biocon faces a new rival to watch — though no direct share loss is proven yet.
When it plays out
Immediate
1-7 days: sentiment-only uptick in Dr Reddy's shares on the launch headline; rivals and suppliers barely move with no price or sales data.
Medium term
1-6 months: prescription ramp, tender wins and early sales reports show whether Nivorz wins share; Biocon may answer with pricing or new launches of its own.
Short term
1-4 weeks: watch for the launch price, approved uses, hospital uptake and management commentary on the biosimilar pipeline — each detail re-prices the story.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 2 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | SELL | 3,57,516 | ₹1,123.68 |
| 2 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | BUY | 3,57,516 | ₹1,123.40 |
| 1 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | BUY | 18,76,359 | ₹1,068.22 |
| 1 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | SELL | 18,47,308 | ₹1,066.89 |
| 1 Sep 2026 | IRAGE BROKING SERVICES LLP | SELL | 9,28,711 | ₹1,057.96 |
| 1 Sep 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | SELL | 8,42,160 | ₹1,063.88 |
| 1 Sep 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | BUY | 8,42,160 | ₹1,063.42 |
| 1 Sep 2026 | IRAGE BROKING SERVICES LLP | BUY | 7,52,199 | ₹1,079.32 |
| 1 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | SELL | 6,67,966 | ₹1,105.17 |
| 1 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | BUY | 6,67,966 | ₹1,104.29 |
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 5 Oct 2026 | RAMAN PRASAD VERMA · Designated Person | SELL | 17,000 | 1.99 |
| 5 Oct 2026 | SUMAN PODDER · Designated Person | SELL | 15,000 | 1.77 |
| 5 Oct 2026 | DHARM SHANKER PANDEY · Designated Person | SELL | 12,470 | 1.46 |
| 5 Oct 2026 | MITESH PATEL · Designated Person | SELL | 11,500 | 1.34 |
| 5 Oct 2026 | JITENDRA SHARMA · Designated Person | SELL | 9,200 | 1.07 |
| 5 Oct 2026 | SUNIL KUMAR PANDEY · Designated Person | SELL | 8,500 | 1.01 |
| 5 Oct 2026 | RAJESH BHIMRAO MESHRAM · Designated Person | SELL | 7,000 | 0.81 |
| 5 Oct 2026 | DR.PRATIMA KHATRI · Designated Person | SELL | 5,500 | 0.65 |
| 5 Oct 2026 | VIVEK ASTHANA · Designated Person | SELL | 5,500 | 0.58 |
| 5 Oct 2026 | SACHIN MADHUKAR CHAUDHARI · Designated Person | SELL | 2,500 | 0.29 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY2722 Sep 2026
- Results presentation30 Jun 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.